<DOC>
	<DOCNO>NCT00590603</DOCNO>
	<brief_summary>This phase I dose escalation study estimate maximum tolerate dose ( MTD ) novel combination Arsenic , Ascorbic Acid Velcade , follow phase II study conduct use MTD estimate phase I portion .</brief_summary>
	<brief_title>Trisenox , Ascorbic Acid Bortezomib Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>Despite fact high dose therapy autologous transplant prolong life patient multiple myeloma ( MM ) , study appear continuously decline event free survival follow auto-transplant indicate patient cured approach . A high percentage patient relapse post transplant set candidate additional chemotherapy . We therefore , investigate novel strategy control disease post transplant setting . The key theoretical issue study whether concomitant Trisenox would permit use less toxic dos Velcade , result less toxic equally effective regimen . Phase I study us dose escalation estimate maximum tolerate dose Arsenic , Ascorbic Acid Velcade . Phase II subsequent treatment phase use maximum tolerate dose Phase I . In absence treatment delay due adverse event , treatment may continue 6 cycle , plus two additional cycle patient achieve good response .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<criteria>Diagnosis relapsed/refractory multiple myeloma . Patients must measurable disease , define localized plasmacytoma , detectable Mspike serum protein electrophoresis ( SPEP ) and/or urine protein electrophoresis ( UPEP ) , free light chain assay , bone lytic lesion and/or bone marrow infiltration atypical plasmacells . Patients must least four week since prior therapy . Patients exclude prior regimen receive long meet requirement . Adequate organ function , patient elevate creatinine due myeloma exclude Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Serum potassium great 4.0 milliequivalent ( mEq ) /dL serum magnesium great 1.8 mg/dL . If electrolyte specify limit baseline laboratory test , supplemental electrolyte administer bring serum concentration level administer arsenic trioxide . Patients may receive investigational agent . History allergic reaction attribute compound similar chemical biologic composition Bortezomib , Trisenox , Ascorbic acid , agent use study . Corrected QT interval ( QTc ) interval great 460 msec presence serum potassium great equal 4.0 mEq/L magnesium great equal 1.8 mg/dL , underlie conduction disease prevents measurement QTc interval . History ventricular tachycardia cardiac arrhythmia require placement automate intraventricular cardiac defibrillator therapy class I class II antiarrhythmic drug . Ejection fraction ( EF ) multigated acquisition ( MUGA ) scan less 35 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Multiple myeloma</keyword>
</DOC>